CN107049935A - 取代β‑环糊精稳定的泊沙康唑静脉输注液制剂 - Google Patents
取代β‑环糊精稳定的泊沙康唑静脉输注液制剂 Download PDFInfo
- Publication number
- CN107049935A CN107049935A CN201710169203.7A CN201710169203A CN107049935A CN 107049935 A CN107049935 A CN 107049935A CN 201710169203 A CN201710169203 A CN 201710169203A CN 107049935 A CN107049935 A CN 107049935A
- Authority
- CN
- China
- Prior art keywords
- posaconazole
- composition
- captisol
- infection
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 title claims abstract description 166
- 229960001589 posaconazole Drugs 0.000 title claims abstract description 165
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 title claims abstract description 102
- 229960004853 betadex Drugs 0.000 title abstract description 97
- 229920000858 Cyclodextrin Polymers 0.000 title abstract description 17
- 239000001116 FEMA 4028 Substances 0.000 title abstract description 4
- 239000012669 liquid formulation Substances 0.000 title abstract description 4
- 235000011175 beta-cyclodextrine Nutrition 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 claims abstract description 83
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 21
- 238000001990 intravenous administration Methods 0.000 claims abstract description 13
- 239000002738 chelating agent Substances 0.000 claims abstract description 8
- 230000004048 modification Effects 0.000 claims abstract description 4
- 238000012986 modification Methods 0.000 claims abstract description 4
- 241001465754 Metazoa Species 0.000 claims description 27
- 239000007787 solid Substances 0.000 claims description 26
- 208000015181 infectious disease Diseases 0.000 claims description 25
- 238000001802 infusion Methods 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 15
- 241000233866 Fungi Species 0.000 claims description 14
- 238000001556 precipitation Methods 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical class C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 239000003085 diluting agent Substances 0.000 claims description 10
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims description 9
- 206010007134 Candida infections Diseases 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 241000222122 Candida albicans Species 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 201000003984 candidiasis Diseases 0.000 claims description 7
- 210000003300 oropharynx Anatomy 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 206010030154 Oesophageal candidiasis Diseases 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000003513 alkali Substances 0.000 claims description 6
- 229940121375 antifungal agent Drugs 0.000 claims description 6
- 201000005655 esophageal candidiasis Diseases 0.000 claims description 6
- -1 polyenoid Chemical compound 0.000 claims description 6
- 206010001935 American trypanosomiasis Diseases 0.000 claims description 5
- 201000002909 Aspergillosis Diseases 0.000 claims description 5
- 208000036641 Aspergillus infections Diseases 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 239000003429 antifungal agent Substances 0.000 claims description 5
- 208000024908 graft versus host disease Diseases 0.000 claims description 5
- 230000003071 parasitic effect Effects 0.000 claims description 5
- 230000002093 peripheral effect Effects 0.000 claims description 5
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 claims description 4
- 208000024699 Chagas disease Diseases 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 108010049047 Echinocandins Chemical class 0.000 claims description 3
- CTETYYAZBPJBHE-UHFFFAOYSA-N Haloprogin Chemical compound ClC1=CC(Cl)=C(OCC#CI)C=C1Cl CTETYYAZBPJBHE-UHFFFAOYSA-N 0.000 claims description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 3
- 208000037026 Invasive Fungal Infections Diseases 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 206010061418 Zygomycosis Diseases 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 230000002155 anti-virotic effect Effects 0.000 claims description 3
- 229960001906 haloprogin Drugs 0.000 claims description 3
- 238000002649 immunization Methods 0.000 claims description 3
- 230000003053 immunization Effects 0.000 claims description 3
- 201000007524 mucormycosis Diseases 0.000 claims description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 3
- 150000003431 steroids Chemical class 0.000 claims description 3
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 239000005864 Sulphur Substances 0.000 claims description 2
- 208000024340 acute graft versus host disease Diseases 0.000 claims description 2
- 230000001967 antemetic effect Effects 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 208000017760 chronic graft versus host disease Diseases 0.000 claims description 2
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 claims description 2
- 229960003749 ciclopirox Drugs 0.000 claims description 2
- 230000003750 conditioning effect Effects 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 230000001629 suppression Effects 0.000 claims description 2
- 229960004880 tolnaftate Drugs 0.000 claims description 2
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 claims description 2
- 230000002051 biphasic effect Effects 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 8
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 abstract description 4
- 238000006467 substitution reaction Methods 0.000 abstract description 3
- 239000007864 aqueous solution Substances 0.000 abstract description 2
- 239000002904 solvent Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 84
- 238000002360 preparation method Methods 0.000 description 50
- 238000010790 dilution Methods 0.000 description 25
- 239000012895 dilution Substances 0.000 description 25
- 238000000034 method Methods 0.000 description 24
- 238000005352 clarification Methods 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- 238000009472 formulation Methods 0.000 description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- 238000011160 research Methods 0.000 description 17
- 239000000523 sample Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical class [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 239000008215 water for injection Substances 0.000 description 12
- 210000003462 vein Anatomy 0.000 description 11
- 239000000825 pharmaceutical preparation Substances 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 229940126534 drug product Drugs 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 241000589516 Pseudomonas Species 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 239000002504 physiological saline solution Substances 0.000 description 8
- 210000004215 spore Anatomy 0.000 description 8
- 206010018910 Haemolysis Diseases 0.000 description 7
- 230000008588 hemolysis Effects 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 230000036470 plasma concentration Effects 0.000 description 7
- 241000223600 Alternaria Species 0.000 description 6
- 241000223682 Exophiala Species 0.000 description 6
- 239000006184 cosolvent Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 6
- 235000011121 sodium hydroxide Nutrition 0.000 description 6
- 241000228212 Aspergillus Species 0.000 description 5
- 239000008121 dextrose Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 4
- 241000235389 Absidia Species 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 241001019659 Acremonium <Plectosphaerellaceae> Species 0.000 description 4
- 241001480043 Arthrodermataceae Species 0.000 description 4
- 241000221198 Basidiomycota Species 0.000 description 4
- 241000335423 Blastomyces Species 0.000 description 4
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 4
- 241000223203 Coccidioides Species 0.000 description 4
- 241000222511 Coprinus Species 0.000 description 4
- 241000223208 Curvularia Species 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 241001480035 Epidermophyton Species 0.000 description 4
- 241000122862 Fonsecaea Species 0.000 description 4
- 241000223218 Fusarium Species 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 241000235649 Kluyveromyces Species 0.000 description 4
- 241000222722 Leishmania <genus> Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241001236817 Paecilomyces <Clavicipitaceae> Species 0.000 description 4
- 241000228143 Penicillium Species 0.000 description 4
- 241000235648 Pichia Species 0.000 description 4
- 241000235402 Rhizomucor Species 0.000 description 4
- 241000235527 Rhizopus Species 0.000 description 4
- 241000235070 Saccharomyces Species 0.000 description 4
- 241000222480 Schizophyllum Species 0.000 description 4
- 241001149962 Sporothrix Species 0.000 description 4
- 241000736854 Syncephalastrum Species 0.000 description 4
- 241000223238 Trichophyton Species 0.000 description 4
- 241000223230 Trichosporon Species 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000037304 dermatophytes Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229940102223 injectable solution Drugs 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 3
- 241001465178 Bipolaris Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000004554 Leishmaniasis Diseases 0.000 description 3
- 241000223596 Pseudallescheria Species 0.000 description 3
- 241000224526 Trichomonas Species 0.000 description 3
- 241000223104 Trypanosoma Species 0.000 description 3
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 3
- 229960003942 amphotericin b Drugs 0.000 description 3
- 150000003851 azoles Chemical class 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 3
- 229960004884 fluconazole Drugs 0.000 description 3
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 3
- 230000009021 linear effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 2
- 240000000073 Achillea millefolium Species 0.000 description 2
- 235000007754 Achillea millefolium Nutrition 0.000 description 2
- 241000187362 Actinomadura Species 0.000 description 2
- 241000191412 Alternaria infectoria Species 0.000 description 2
- 108010064760 Anidulafungin Proteins 0.000 description 2
- 241000293035 Apophysomyces Species 0.000 description 2
- 241000222490 Bjerkandera Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108010020326 Caspofungin Proteins 0.000 description 2
- 241001633123 Cladophialophora Species 0.000 description 2
- 241001527609 Cryptococcus Species 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 241000223924 Eimeria Species 0.000 description 2
- 241000228402 Histoplasma Species 0.000 description 2
- 241001444195 Madurella Species 0.000 description 2
- 241001480037 Microsporum Species 0.000 description 2
- 241000235395 Mucor Species 0.000 description 2
- 208000001388 Opportunistic Infections Diseases 0.000 description 2
- 241001537205 Paracoccidioides Species 0.000 description 2
- 208000031956 Phaehyphomycosis Diseases 0.000 description 2
- 201000011404 Phaeohyphomycosis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000233870 Pneumocystis Species 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 241001524162 Ramichloridium Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000235343 Saccharomycetales Species 0.000 description 2
- 241000235342 Saccharomycetes Species 0.000 description 2
- 241000293026 Saksenaea Species 0.000 description 2
- 241000132889 Scedosporium Species 0.000 description 2
- 241000223255 Scytalidium Species 0.000 description 2
- 229920001304 Solutol HS 15 Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 241000223109 Trypanosoma cruzi Species 0.000 description 2
- 241000235013 Yarrowia Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 229960003348 anidulafungin Drugs 0.000 description 2
- JHVAMHSQVVQIOT-MFAJLEFUSA-N anidulafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@@H](C)O)[C@H](O)[C@@H](O)C=2C=CC(O)=CC=2)[C@@H](C)O)=O)C=C1 JHVAMHSQVVQIOT-MFAJLEFUSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 description 2
- 229960003034 caspofungin Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 2
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 2
- 229960004130 itraconazole Drugs 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000002969 morbid Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 201000000317 pneumocystosis Diseases 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- 210000003046 sporozoite Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-Hydroxyoctadecanoic acid Natural products CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 206010005098 Blastomycosis Diseases 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 206010033767 Paracoccidioides infections Diseases 0.000 description 1
- 201000000301 Paracoccidioidomycosis Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 206010042938 Systemic candida Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000000919 anti-host Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 231100000313 clinical toxicology Toxicity 0.000 description 1
- 201000003486 coccidioidomycosis Diseases 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229960001270 d- tartaric acid Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940048879 dl tartaric acid Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 229960001269 glycine hydrochloride Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000006207 intravenous dosage form Substances 0.000 description 1
- 208000036732 invasive candidiasis Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-N levotartaric acid Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229940113115 polyethylene glycol 200 Drugs 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229940013998 posaconazole 18 mg/ml Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960000580 terconazole Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35970110P | 2010-06-29 | 2010-06-29 | |
| US61/359701 | 2010-06-29 | ||
| CN2011800314889A CN102958528A (zh) | 2010-06-29 | 2011-06-24 | 取代β-环糊精稳定的泊沙康唑静脉输注液制剂 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011800314889A Division CN102958528A (zh) | 2010-06-29 | 2011-06-24 | 取代β-环糊精稳定的泊沙康唑静脉输注液制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107049935A true CN107049935A (zh) | 2017-08-18 |
Family
ID=45441500
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710169203.7A Pending CN107049935A (zh) | 2010-06-29 | 2011-06-24 | 取代β‑环糊精稳定的泊沙康唑静脉输注液制剂 |
| CN2011800314889A Pending CN102958528A (zh) | 2010-06-29 | 2011-06-24 | 取代β-环糊精稳定的泊沙康唑静脉输注液制剂 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011800314889A Pending CN102958528A (zh) | 2010-06-29 | 2011-06-24 | 取代β-环糊精稳定的泊沙康唑静脉输注液制剂 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9023790B2 (el) |
| EP (3) | EP3391890B1 (el) |
| JP (1) | JP6008849B2 (el) |
| KR (1) | KR101834024B1 (el) |
| CN (2) | CN107049935A (el) |
| AU (1) | AU2011276680B2 (el) |
| BR (1) | BR112012033077B8 (el) |
| CA (1) | CA2802929C (el) |
| CY (1) | CY1124690T1 (el) |
| DK (1) | DK3391890T3 (el) |
| ES (1) | ES2893444T3 (el) |
| HR (1) | HRP20211686T1 (el) |
| HU (1) | HUE056581T2 (el) |
| LT (1) | LT3391890T (el) |
| MX (2) | MX338685B (el) |
| PL (1) | PL3391890T3 (el) |
| PT (1) | PT3391890T (el) |
| RS (1) | RS62583B1 (el) |
| SI (1) | SI3391890T1 (el) |
| WO (1) | WO2012005973A1 (el) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110711174A (zh) * | 2018-07-11 | 2020-01-21 | 郑州泰丰制药有限公司 | 一种泊沙康唑注射液中间体溶液配制方法 |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090175810A1 (en) | 2008-01-03 | 2009-07-09 | Gareth Winckle | Compositions and methods for treating diseases of the nail |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| DK3391890T3 (da) | 2010-06-29 | 2021-11-01 | Merck Sharp & Dohme | Intravenøse posaconazolopløsningsformuleringer, der er stabiliseret ved hjælp af substitueret beta-cyclodextrin |
| US8039494B1 (en) | 2010-07-08 | 2011-10-18 | Dow Pharmaceutical Sciences, Inc. | Compositions and methods for treating diseases of the nail |
| PL2814849T3 (pl) | 2012-02-15 | 2020-07-27 | Cydex Pharmaceuticals, Inc. | Sposób wytwarzania pochodnych cyklodekstryny |
| CN110433291B (zh) | 2013-10-03 | 2023-04-28 | 博世健康爱尔兰有限公司 | 稳定的艾菲康唑组合物 |
| CN104546724A (zh) * | 2013-10-12 | 2015-04-29 | 博瑞生物医药技术(苏州)有限公司 | 一种抗真菌药的固体分散体 |
| US10245257B2 (en) | 2013-11-22 | 2019-04-02 | Dow Pharmaceutical Sciences, Inc. | Anti-infective methods, compositions, and devices |
| CN105879041A (zh) * | 2014-11-14 | 2016-08-24 | 北京赛林泰医药技术有限公司 | 一种泊沙康唑口服液及其制备方法 |
| EA201791100A1 (ru) * | 2014-11-19 | 2017-11-30 | Гуфик Байосайенсиз Лимитед | Способ получения парентерального состава на основе анидулафунгина |
| CN104473871B (zh) * | 2014-11-28 | 2017-03-08 | 济南康和医药科技有限公司 | 一种泊沙康唑脂肪乳注射液及其制备方法 |
| CN106265534A (zh) * | 2015-05-25 | 2017-01-04 | 江苏正大丰海制药有限公司 | 一种泊沙康唑冻干粉针剂的制备方法 |
| CN106511262A (zh) * | 2015-09-11 | 2017-03-22 | 上海美悦生物科技发展有限公司 | 一种泊沙康唑口服溶液剂及其制备方法 |
| WO2017133632A1 (zh) | 2016-02-04 | 2017-08-10 | 武汉朗来科技发展有限公司 | 泊沙康唑衍生物、其药物组合物和用途 |
| JP2019535722A (ja) | 2016-11-18 | 2019-12-12 | アイキュリス アンチ−インフェクティブ キュアズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 修飾シクロデキストリン及び酸性化剤に基づくアミジン置換ベータ−ラクタム化合物の新規製剤、それらの製造及び抗菌医薬組成物としての使用 |
| WO2020139209A1 (en) * | 2018-12-28 | 2020-07-02 | Polifarma Ilac Sanayi Ve Ticaret Anonim Srketi | Stable injectable posaconazole formulations comprising cyclodextrin and sugar |
| US20230285391A1 (en) * | 2020-06-06 | 2023-09-14 | Inventia Healthcare Limited | Stable liquid compositions of posaconazole |
| WO2023148763A1 (en) * | 2022-02-01 | 2023-08-10 | Cipla Limited | Injectable pharmaceutical compositions of azole antifungal agents |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007047253A2 (en) * | 2005-10-11 | 2007-04-26 | Eastman Chemical Company | Pharmaceutical formulations of cyclodextrins and antifungal azole compounds |
| CN101039668A (zh) * | 2004-08-13 | 2007-09-19 | 先灵-普劳有限公司 | 包含抗菌素、三唑和皮质类固醇的药物制剂 |
| WO2008034040A1 (en) * | 2006-09-15 | 2008-03-20 | Regents Of The University Of Minnesota | Topiramate compositions and methods for their use |
| CN101370453A (zh) * | 2005-12-14 | 2009-02-18 | 扎尔斯制药公司 | 用于皮肤输送药物的组合物和方法 |
| CN101495096A (zh) * | 2006-05-30 | 2009-07-29 | 伊兰制药国际有限公司 | 纳米微粒泊沙康唑制剂 |
| US20090270348A1 (en) * | 2008-04-28 | 2009-10-29 | Antle Vincent | Sulfoalkyl Ether Cyclodextrin Compositions |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5257985A (en) | 1989-12-04 | 1993-11-02 | Richard Puhl | Multi-chamber intravenous bag apparatus |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5703079A (en) | 1993-12-21 | 1997-12-30 | Schering Corporation | Tetrahydrofuran antifungals |
| US5661151A (en) | 1993-12-21 | 1997-08-26 | Schering Corporation | Tetrahydrofuran antifungals |
| ES2159623T3 (es) | 1993-12-21 | 2001-10-16 | Schering Corp | Antifungicos de tetrahidrofurano. |
| US5834472A (en) | 1996-05-24 | 1998-11-10 | Schering Corporation | Antifungal composition with enhanced bioavailability |
| US5972381A (en) | 1996-06-28 | 1999-10-26 | Schering Corporation | Solid solution of an antifungal agent with enhanced bioavailability |
| GB9713149D0 (en) | 1997-06-21 | 1997-08-27 | Pfizer Ltd | Pharmaceutical formulations |
| US6713481B1 (en) | 1997-10-17 | 2004-03-30 | David R. Andrews | Crystalline antifungal polymorph |
| US20030099674A1 (en) | 2001-08-11 | 2003-05-29 | Chen Andrew X. | Lyophilized injectable formulations containing paclitaxel or other taxoid drugs |
| EP1499274B1 (en) | 2002-04-30 | 2009-12-16 | Otsuka Pharmaceutical Factory, Inc. | Multiple-chamber medical container and bag for enclosing same |
| BRPI0411043A (pt) * | 2003-06-06 | 2006-07-11 | Sankyo Co | composição medicinal |
| US20060160823A1 (en) | 2004-05-28 | 2006-07-20 | Leonore Witchey-Lakshmanan | Particulate-stabilized injectable pharmaceutical compositions of Posaconazole |
| US20060009469A1 (en) * | 2004-05-28 | 2006-01-12 | Leonore Witchey-Lakshmanan | Particulate-stabilized injectable pharmacutical compositions of posaconazole |
| RU2006146555A (ru) * | 2004-05-28 | 2008-07-20 | Шеринг Копрорейшн (Us) | Инъецируемые фармацевтические композиции позаконазола со стабилизированными частицами |
| WO2006098345A1 (ja) * | 2005-03-15 | 2006-09-21 | Ajinomoto Co., Inc. | 薬剤移送具 |
| US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
| JP2010515762A (ja) | 2007-01-16 | 2010-05-13 | エンゾン ファーマスーティカルズ インコーポレイテッド | ポサコナゾール−ポリマー複合体、並びに、ポサコナゾールおよびそのポリマー複合体を使用した治療方法 |
| WO2009018069A2 (en) | 2007-07-30 | 2009-02-05 | Cydex Pharmaceuticals, Inc | Mixtures of cyclodextrin derivatives |
| EP2334651A2 (en) * | 2008-07-24 | 2011-06-22 | Theravance, Inc. | Dual-acting antihypertensive agents |
| DK3391890T3 (da) | 2010-06-29 | 2021-11-01 | Merck Sharp & Dohme | Intravenøse posaconazolopløsningsformuleringer, der er stabiliseret ved hjælp af substitueret beta-cyclodextrin |
-
2011
- 2011-06-24 DK DK18171672.1T patent/DK3391890T3/da active
- 2011-06-24 EP EP18171672.1A patent/EP3391890B1/en active Active
- 2011-06-24 RS RS20211325A patent/RS62583B1/sr unknown
- 2011-06-24 EP EP21192006.1A patent/EP3960185A1/en active Pending
- 2011-06-24 SI SI201132006T patent/SI3391890T1/sl unknown
- 2011-06-24 HU HUE18171672A patent/HUE056581T2/hu unknown
- 2011-06-24 PT PT181716721T patent/PT3391890T/pt unknown
- 2011-06-24 MX MX2012015168A patent/MX338685B/es active IP Right Grant
- 2011-06-24 BR BR112012033077A patent/BR112012033077B8/pt active IP Right Grant
- 2011-06-24 CN CN201710169203.7A patent/CN107049935A/zh active Pending
- 2011-06-24 PL PL18171672T patent/PL3391890T3/pl unknown
- 2011-06-24 WO PCT/US2011/041715 patent/WO2012005973A1/en active Application Filing
- 2011-06-24 US US13/704,145 patent/US9023790B2/en active Active
- 2011-06-24 EP EP11804061.7A patent/EP2588116A4/en not_active Withdrawn
- 2011-06-24 KR KR1020127034087A patent/KR101834024B1/ko active IP Right Grant
- 2011-06-24 CA CA2802929A patent/CA2802929C/en active Active
- 2011-06-24 HR HRP20211686TT patent/HRP20211686T1/hr unknown
- 2011-06-24 JP JP2013518498A patent/JP6008849B2/ja active Active
- 2011-06-24 LT LTEP18171672.1T patent/LT3391890T/lt unknown
- 2011-06-24 CN CN2011800314889A patent/CN102958528A/zh active Pending
- 2011-06-24 ES ES18171672T patent/ES2893444T3/es active Active
- 2011-06-24 AU AU2011276680A patent/AU2011276680B2/en active Active
-
2012
- 2012-12-19 MX MX2016001250A patent/MX346901B/es unknown
-
2015
- 2015-03-25 US US14/668,683 patent/US9358297B2/en active Active
-
2021
- 2021-11-03 CY CY20211100950T patent/CY1124690T1/el unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101039668A (zh) * | 2004-08-13 | 2007-09-19 | 先灵-普劳有限公司 | 包含抗菌素、三唑和皮质类固醇的药物制剂 |
| WO2007047253A2 (en) * | 2005-10-11 | 2007-04-26 | Eastman Chemical Company | Pharmaceutical formulations of cyclodextrins and antifungal azole compounds |
| CN101370453A (zh) * | 2005-12-14 | 2009-02-18 | 扎尔斯制药公司 | 用于皮肤输送药物的组合物和方法 |
| CN101495096A (zh) * | 2006-05-30 | 2009-07-29 | 伊兰制药国际有限公司 | 纳米微粒泊沙康唑制剂 |
| WO2008034040A1 (en) * | 2006-09-15 | 2008-03-20 | Regents Of The University Of Minnesota | Topiramate compositions and methods for their use |
| US20090270348A1 (en) * | 2008-04-28 | 2009-10-29 | Antle Vincent | Sulfoalkyl Ether Cyclodextrin Compositions |
Non-Patent Citations (1)
| Title |
|---|
| 刘恒平: ""伊曲康唑包合物的制备与研究"", 《中国生化药物杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110711174A (zh) * | 2018-07-11 | 2020-01-21 | 郑州泰丰制药有限公司 | 一种泊沙康唑注射液中间体溶液配制方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107049935A (zh) | 取代β‑环糊精稳定的泊沙康唑静脉输注液制剂 | |
| JP7489965B2 (ja) | マルチキナーゼ阻害剤のエマルジョン製剤 | |
| US20080096967A1 (en) | Formulations for Injection of Catecholic Butanes, Including Ndga Compounds, Into Animals | |
| CN101959519A (zh) | 用于玻璃体内注射的低粘度、高度絮凝的曲安奈德混悬液 | |
| CN110177576A (zh) | 用于眼用活性药物成分递送的固体环糊精复合物的制备 | |
| CN103402543B (zh) | 用于胃肠外施用的吡咯药物制剂及其制备方法和治疗对吡咯化合物敏感的疾病的使用方法 | |
| WO2022160971A1 (zh) | 一种含有难溶性药物的浓缩液以及由其制备的乳剂 | |
| CN103079559A (zh) | 包含胺碘酮及其盐的制剂及其制造和使用方法 | |
| Hashem et al. | Glibenclamide nanosuspension inhaler: development, in vitro and in vivo assessment | |
| Almehmady et al. | Enhancing the antifungal activity and ophthalmic transport of fluconazole from PEGylated polycaprolactone loaded nanoparticles | |
| Valls et al. | Transcorneal permeation in a corneal device of non-steroidal anti-inflammatory drugs in drug delivery systems | |
| WO2007009355A1 (fr) | Injection de paclitaxel et sa méthode de préparation | |
| Soe et al. | A Current Overview of Cyclodextrin-Based Nanocarriers for Enhanced Antifungal Delivery | |
| Szalai et al. | Design and optimization of in situ gelling mucoadhesive eye drops containing dexamethasone | |
| JP2019506377A (ja) | 薬物包接化合物、その製剤、およびそのための製造方法 | |
| JP2018512395A (ja) | タキサン−シクロデキストリン複合体を含む医薬組成物、作成方法、および使用方法 | |
| RU2575768C2 (ru) | Составы внутривенных растворов позаконазола, стабилизированные посредством замещенного бета-циклодекстрина | |
| CN101150956B (zh) | 用于注射入动物的包括ndga化合物的儿茶酚丁烷配方 | |
| JP2019504042A (ja) | 経口製剤およびその製造方法 | |
| Beniwal et al. | Descriptive Assessment Of Cyclodextrin Based Clotrimazole Nanogel For Vaginal Conveyance To Treat Fungal Infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20220905 Address after: new jersey Applicant after: MERCK SHARP & DOHME B.V. Address before: new jersey Applicant before: MERCK SHARP & DOHME Corp. |
|
| TA01 | Transfer of patent application right | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170818 |
|
| RJ01 | Rejection of invention patent application after publication |